Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1281-1300 of 1,307 trials

Advanced Breast Cancer: PF-07248144 with Fulvestrant

We are studying a new treatment combining PF-07248144 and fulvestrant for adults with hormone receptor-positive, HER2-negative advanced breast cancer. This trial aims to see if it helps patients whose cancer has progressed after prior therapy.

Hormone Receptor-Positive, HER2-Negative Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Breast Cancer: Patritumab Deruxtecan vs. Standard Treatment

We are studying a new medication for patients with hormone receptor-positive, HER2-negative advanced breast cancer. The goal is to see if it works better than the current treatment options.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

HIV-1 Prevention: MK-8527 Oral Medication

We are studying a new once-monthly pill, MK-8527, to see if it can effectively prevent HIV-1 infection compared to a daily treatment. The trial will also assess how safe and tolerable this new medication is for participants.

HIV-1>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Alzheimer's Disease: KarXT + KarX-EC Treatment

We are studying a new combination treatment for agitation in people with Alzheimer's disease. The goal is to see if it can reduce agitation symptoms better than a placebo.

Alzheimer's Disease Agitation3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

We are studying the effects of ELA026 on survival in patients with sHLH triggered by lymphoma. This trial will help us understand how well this treatment works and its safety.

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)3-6 monthsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

Primary Aldosteronism: Baxdrostat Study

We are investigating how safe and effective baxdrostat is for adults with primary aldosteronism. The goal is to see if it can improve blood pressure and other health measures compared to a placebo.

Primary Hyperaldosteronism1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Alzheimer’s Disease: KarXT + KarX-EC Treatment

We are studying a new treatment for cognitive impairment in people with mild to moderate Alzheimer’s disease. The trial will check if it helps improve thinking skills and daily activities, while also ensuring safety.

Mild to Moderate Alzheimer's Disease1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesNeurologyPsychiatry

Botulinum Toxin Treatment: Patient Satisfaction Study

We are examining how satisfied patients are with split doses of botulinum toxin compared to a control group. The study also looks at the safety of this treatment over time.

Frown Lines6-12 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

Congenital Pseudarthrosis of the Tibia: NVD003 Treatment Study

We are evaluating how effective and safe NVD003 is for children undergoing surgery for congenital pseudarthrosis of the tibia. The study will also look at its impact on bone healing and quality of life.

Congenital Pseudarthrosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Parkinson's Disease: Lecigon® Therapy

We are studying a new treatment combining levodopa and entacapone for people with Parkinson's disease. The goal is to see if it helps reduce certain symptoms and improve overall well-being compared to standard treatments.

Parkinson's Disease>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyPsychiatry

Obesity Treatment: Orforglipron Tablet Study

We are investigating how well a new daily tablet helps people with obesity or overweight, both with and without type 2 diabetes, in reducing weight and improving blood sugar levels compared to a placebo.

ObesityOverweightType 2 Diabetes1-2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Multiple Sclerosis: Subcutaneous vs. Intravenous Ublituximab

We are studying how a new subcutaneous injection of ublituximab compares to the intravenous version for people with relapsing multiple sclerosis. The goal is to evaluate its safety and effectiveness in managing the condition.

Relapsing Multiple SclerosisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementNeurology

Chronic Subdural Hematoma: Timing of Anticoagulation

We are studying whether starting blood-thinning medication early or later helps patients with atrial fibrillation recover better after surgery for chronic subdural hematoma. This research looks at potential risks and overall health outcomes.

Chronic Subdural HematomaAtrial Fibrillation3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal MedicineNeurology

Type 2 Diabetes: Vicadrostat and Empagliflozin Study

We are testing the combination of vicadrostat and empagliflozin in people with type 2 diabetes, high blood pressure, and heart disease. The goal is to see if this combination can improve heart health compared to a placebo.

Type 2 DiabetesHypertensionCardiovascular Disease>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine

IVF/ICSI: Low Dose hCG Priming for Women with Diminished Ovarian Reserve

We are investigating whether low dose hCG priming can help women with diminished ovarian reserve retrieve more eggs during IVF/ICSI. This study aims to confirm earlier findings that suggest a significant increase in egg retrieval.

Infertility Due to Diminished Ovarian Reserve>2 yearsConfirmation phase (III)Standard MedicinesGynecology and Obstetrics

Durvalumab for Limited Stage Small Cell Lung Cancer

We are studying the safety and effectiveness of durvalumab for patients with limited stage small cell lung cancer who have not progressed after chemoradiation therapy. This trial also looks at how the treatment affects quality of life and disease symptoms.

Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Cerebrolysin for Recovery After Ischemic Stroke

We are studying whether Cerebrolysin can improve upper limb function and overall recovery in patients after an ischemic stroke. Participants will be compared to those receiving a placebo to assess various health outcomes.

Ischaemic Stroke3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesNeurology

Chronic Dialysis: Patiromer for Potassium Management

We are studying whether patiromer can help patients on chronic dialysis eat more potassium-rich foods safely. This trial looks at its impact on health-related quality of life and dietary restrictions.

End Stage Kidney DiseaseConfirmation phase (III)Investigational MedicinesNephrology

Colonoscopy Prep: Mannitol vs. Plenvu®

We are studying whether mannitol is as effective and acceptable as Plenvu® for bowel preparation before a colonoscopy. This trial aims to ensure patient comfort and safety during the procedure.

Colonoscopy3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterology

Covert Brain Infarction: Antiplatelet and Lipid-Lowering Treatments

We are studying whether adding antiplatelet and cholesterol-lowering medications can help patients with covert brain infarctions reduce serious health risks. This trial will also assess the impact on cognitive health and overall mortality.

Covert Brain Infarct>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology